The Supreme Court today refused to stay the Madras High Court ruling that set aside Swiss drug major F Hoffman-La Roche's patent related to its anti-infection drug Valganciclovir.
The High Court has set aside the patent as it wanted the Chennai patent office to hear the version of the Tamil Nadu Network of People with HIV/AIDS, a Tamil Nadu-based patient group, which had been opposing the patent before it was granted.
A bench headed by Justice S H Kapadia, while refusing to stay the High Court order, modified it asking the patent office to dispose of the matter by January 31. Besides, it said that the Madras High Court order should not affect another petition of Roche pending before the Bombay High Court, seeking injunction on Cipla's decision to market a copy version of anti-infection drug Valganciclovir, patented by Roche under the brand name Valcept.
It said: "It is made clear that pending further orders of (the) Assistant Controller of Patents, Design and Trademarks" the Bombay High Court shall not dismiss Roche's injunction plea.
The apex court also posted the matter for hearing on February 10.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
